Sofinnova Investments, Inc.
Menlo Park, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.03B2026 Q3+ $274.8M options (notional, not included)
Positions67
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.63.4%
What Changed This Quarter?
Top Holdings
NTRA
Natera
27.8%
GMAB
Genmab A/S
6.7%
IWMPUT
Ishares Tr
6.0%
JAZZ
Jazz Pharmaceuticals
4.2%
VERA
Vera Therapeutics
3.9%
AXSM
Axsome Therapeutics
3.6%
SPTX
Seaport Therapeutics
3.1%
RAPP
Rapport Therapeutics
2.8%
New / Increased
23 new · 14 increased
IWMPUTNEW
Ishares Tr
6.0%
AZNNEW
AstraZeneca
2.7%
QQQPUTNEW
Invesco QQQ Tr
2.4%
LLYNEW
Eli Lilly
2.2%
BMYCALLNEW
Bristol-Myers Squibb
1.9%
AXSM
Axsome Therapeutics
3.6%
+177.9%
DYN
Dyne Therapeutics
1.8%
+51.4%
JAZZ
Jazz Pharmaceuticals
4.2%
+15.6%
Reduced / Exited
20 reduced · 13 sold out
BMY
Bristol-Myers Squibb
0.9%
-62.4%
UTHR
United Therapeutics
0.9%
-52.3%
NKTR
Nektar Therapeutics
0.6%
-53.8%
RCUS
Arcus Biosciences
0.7%
-33.8%
PHVS
N.V. Pharvaris
0.9%
-29.5%
SUPNEXIT
Supernus Pharmaceuticals
2.5%
GILDEXIT
Gilead Sciences
2.2%
COGTEXIT
Cogent Biosciences
2.1%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.